www.89bio.com Open in urlscan Pro
184.106.55.132  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About
   * Overview
   * Management
   * Board of Directors
 * Pipeline
   * Overview
   * Pegozafermin (BIO89-100)
   * FGF21
   * NASH
   * SHTG
   * Clinical Trials
   * Scientific Publications
 * Investors
   * Corporate Profile
   * Press Releases
   * Events & Presentations
   * Corporate Governance
   * Stock Information
   * Financials & Filings
   * Investor Resources
 * Careers
   * Overview
   * Values
   * Benefits
   * Open Jobs
 * Contact


POWERFUL SCIENCE
MEANINGFUL MEDICINES
CHANGING LIVES

89bio is a clinical-stage biopharma company focused on the development and
commercialization of innovative therapies for patients with non-alcoholic
steatohepatitis (NASH), severe hypertrigly-ceridemia (SHTG) and other liver and
cardio-metabolic diseases.

Pegozafermin
(BIO89-100):
A differentiated
FGF21 therapy
An attractive treatment
strategy for NASH
and SHTG
NASH proof-of-concept
phase 1b/2a and
SHTG phase 2 trials


NEWS

05/11/2022 PRESS RELEASE
89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
05/03/2022 PRESS RELEASE
89bio to Participate in Upcoming Investor Conferences
04/26/2022 PRESS RELEASE
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
info@89bio.com

142 Sansome St 2nd Floor,
San Francisco, CA 94104, USA

6 Hamada Street
Herzliya 4673340, Israel

 * Home
 * About
 * Pipeline
 * Investors
 * Careers
 * Contact


© 2022 | 89bio, Inc. All rights reserved.
Trademarks are property of 89bio, Inc. |
Terms of Use | Privacy Statement